Bexagliflozin for type 2 diabetes: an overview of the data

References

• IDF. IDF diabetes atlas 9th edition. 2019 [cited 2021 Apr 2nd]. https://diabetesatlas.org/en.
   Google Scholar
• Xu G, Liu B, Sun Y, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. BMJ 2018;362:k1497.
   PubMed Web of Science ®Google Scholar
• Skinner AC, Ravanbakht SN, Skelton JA, et al. Prevalence of obesity and severe obesity in US children, 1999-2016. Pediatrics. 2018;141(3):e20173459. .
   Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group. Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. .
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–430. .
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmer J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
   PubMed Web of Science ®Google Scholar
• Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011;171(21):1920–1927. .
   PubMedGoogle Scholar
• Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(9713):481–489. .
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. Glycemic Targets: standards of medical care in diabetes-2021. Diabetes Care. 2021 Jan;44(1):S73–S84.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the american college of physicians. Ann Intern Med. 2018;168(8):569–576. .
   PubMed Web of Science ®Google Scholar
• Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-Lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316(3):313–324. .
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1118.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Davidson JA, Del PS. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5–14.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11–26.
   PubMed Web of Science ®Google Scholar
• Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66(1):255–270.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013;62(10):3324–3328.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495–502.
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–415. .
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815–1823. .
   PubMed Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–274. .
   PubMed Web of Science ®Google Scholar
• Liu XY, Zhang N, Chen R, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years. J Diabetes Complications. 2015;29(8):1295–1303. .
   PubMed Web of Science ®Google Scholar
• Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2(5):e001007. .
   PubMed Web of Science ®Google Scholar
• Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015–2022. .
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508–2515. .
   PubMed Web of Science ®Google Scholar
• Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211–220.
   PubMed Web of Science ®Google Scholar
• Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420–428. .
   PubMed Web of Science ®Google Scholar
• Townsend RR, Machin I, Ren J, et al. Reductions in mean 24-Hour ambulatory blood pressure after 6-Week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich). 2016;18(1):43–52.
   PubMed Web of Science ®Google Scholar
• Weber MA, Mansfield TA, Alessi F, et al. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press. 2016;25(2):93–103.
   PubMed Web of Science ®Google Scholar
• Baker WL, Buckley LF, Kelly MS, et al. Effects of Sodium-Glucose cotransporter 2 inhibitors on 24-Hour ambulatory blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6(5). doi: https://doi.org/10.1161/JAHA.117.005686.
   Web of Science ®Google Scholar
• Mazidi M, Rezaie P, Gao H, et al. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6(6). doi: https://doi.org/10.1161/JAHA.116.004007.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Floretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–971. .
   PubMed Web of Science ®Google Scholar
• Kawasoe S, Maruguchi Y, Kajiya S, et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol. 2017;18(1):23. .
   PubMed Web of Science ®Google Scholar
• Herat LY, Matthews VB, Magno AL, et al. An evaluation of empagliflozin and it’s applicability to hypertension as a therapeutic option. Expert Opin Pharmacother. 2020;21(10):1157–1166. .
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Townsend RR, Davies MJ, et al. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017;16(1):29. .
   PubMed Web of Science ®Google Scholar
• Sano M. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation. Ther Adv Cardiovasc Dis. 2020;14:1753944720939383.
   Google Scholar
• Matthews VB, Elliot RH, Rudnicka C, et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens. 2017;35(10):2059–2068. .
   PubMed Web of Science ®Google Scholar
• Herat LY, Magno AL, Rudnicka C, et al. SGLT2 Inhibitor-Induced sympathoinhibition: a novel mechanism for cardiorenal protection. JACC Basic Transl Sci. 2020;5(2):169–179.
   PubMedGoogle Scholar
• Sharaf El Din UAA, Salem MM, Abdulazim DO. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. J Adv Res. 2017;8(5):537–548.
   PubMed Web of Science ®Google Scholar
• Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266(21):3008–3011. .
   PubMed Web of Science ®Google Scholar
• Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821.
   PubMed Web of Science ®Google Scholar
• Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35(7):391–404. .
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458–462. .
   PubMed Web of Science ®Google Scholar
• Forstermann U, Xia N, Li H. Roles of Vascular Oxidative Stress and Nitric Oxide in the pathogenesis of atherosclerosis. Circ Res. 2017;120(4):713–735.
   PubMed Web of Science ®Google Scholar
• Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–1070.
   PubMed Web of Science ®Google Scholar
• Kusaka H, Koibuchi N, Hasegawa Y, et al. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):157. .
   PubMed Web of Science ®Google Scholar
• Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13(1):148. .
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for industry in diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapires to treat type 2 diabetes. 2008 [ cited 2021 Apr 24th]; Available from: https://www.federalregister.gov/documents/2008/12/19/E8-30086/guidance-for-industry-on-diabetes-mellitus-evaluating-cardiovascular-risk-in-new-antidiabetic.
   Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471.
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielson H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–2135.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 373(22): 2117–2128. 2015.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al., Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 377(7): 644–657. 2017.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al., Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 380(4): 347–357. 2019.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Matthews DR, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)–a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217–223 e11.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, De Zeeuw D, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19(3):387–393. .
   PubMed Web of Science ®Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al., Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 381(21): 1995–2008. 2019.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al., Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 383(15): 1413–1424. 2020.
   PubMed Web of Science ®Google Scholar
• Zannad F, Ferreira JP, Pocock SJ, et al., SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 396(10254): 819–829. 2020.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al., Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 380(24): 2295–2306. 2019.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefansson BV, Chertow GM, et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020;35(2):274–282. .
   PubMed Web of Science ®Google Scholar
• Wheeler DC, Stefansson BV, Batiushin M, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020;35(10):1700–1711. .
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefansoon BV, Correa-Rotter R, et al., Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 383(15): 1436–1446. 2020. .
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Wheeler DC, Stefansso BV, et al. Effect of Dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation. 2021;143(5):438–448.
   PubMed Web of Science ®Google Scholar
• Cherney DZI, Dekkers CCJ, Barbour SJ, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020;8(7):582–593.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Kosiborod M, Inzucchi SE, et al. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018;94(1):26–39.
   PubMed Web of Science ®Google Scholar
• Larmour K, Levin A. Slowing Progression in CKD: DAPA CKD and Beyond. Clin J Am Soc Nephrol. 2021;16(7):1117–1119.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Rathore A, Parwani D, et al. An exhaustive perspective on structural insights of SGLT2 inhibitors: a novel class of antidiabetic agent. Eur J Med Chem. 2020;204:112523.
   PubMed Web of Science ®Google Scholar
• PubChem PD Bexagliflozin. 2021. [ cited 2021 May 3rd]; Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Bexagliflozin.
   Google Scholar
• Zhang W, Welihinda A, Mechanic J, et al. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacol Res. 2011;63(4):284–293. .
   PubMed Web of Science ®Google Scholar
• Zhang W, Li X, Ding H, et al. Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humans. Xenobiotica. 2020;50(5):559–569. .
   PubMed Web of Science ®Google Scholar
• Kuchay MS, Farooqui KJ, Mishra SK, et al. In: Islam MS, editors. Glucose lowering efficacy and pleiotropic effects of sodium-glucose cotransporter 2 inhibitors, in Diabetes: from Research to Clinical Practice: Volume 4. Springer International Publishing; 2021. p. 213–230.
   Google Scholar
• Halvorsen YD, Walford G, Thurber T, et al. A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes. Diabetes Obes Metab. 2020;22(4):566–573. .
   PubMed Web of Science ®Google Scholar
• Halvorsen YC, Lock JP, Zhou W, et al. A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. Diabetes Obes Metab. 2019;21(11):2496–2504. .
   PubMed Web of Science ®Google Scholar
• Halvorsen YD, Walford GA, Massaro J, et al. A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metab. 2019;21(10):2248–2256. .
   PubMed Web of Science ®Google Scholar
• Allegretti AS, Zhang W, Zhou W, et al., Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. Am J Kidney Dis. 74(3): 328–337. 2019. .
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Freeman MW, Massaro J, et al. 32-OR: the Bexagliflozin Efficacy and Safety Trial (BEST): a randomized, double-blind, placebo-Controlled, Phase IIII. 2020; 69(1): 32–OR. Clinical Trial. Diabetes.
   Google Scholar
• FDA. FDA approves new treatment for a type of heart failure. 2020 [ cited 2021 May 9th]. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure
   Google Scholar
• Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121–128.
   PubMed Web of Science ®Google Scholar
• AJMC. FDA approves canagliflozin to prevent kidney failure, hospitalization for heart failure. 2019 [ cited 2021 May 9th]. https://www.ajmc.com/view/fda-approves-canagliflozin-to-prevent-kidney-failure-hospitalization-for-heart-failure
   Google Scholar
• ACC. FDA approves dapagliflozin to treat CKD. 2021 [ cited 2021 May 9th]. https://www.acc.org/latest-in-cardiology/articles/2021/05/03/19/11/fda-approves-dapagliflozin-to-treat-ckd.
   Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–2498.
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221–228. .
   PubMed Web of Science ®Google Scholar
• ADA. 9. pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Supplement 1):S111–S124.
   PubMed Web of Science ®Google Scholar
• Li D, Wang T, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348–355. .
   PubMed Web of Science ®Google Scholar
• Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014;16(12):875–882. .
   PubMed Web of Science ®Google Scholar
• Weir MR, Kline I, Xie J, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014;30(9):1759–1768. .
   PubMed Web of Science ®Google Scholar
• Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017;33(5):e2886.
   PubMed Web of Science ®Google Scholar
• Watts NB, Bilezikian JP, Usiskin K, et al. Effects of Canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101(1):157–166.
   PubMed Web of Science ®Google Scholar
• Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016;18(12):1199–1206.
   PubMed Web of Science ®Google Scholar
• Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes Metab. 2018;20(6):1531–1534.
   PubMed Web of Science ®Google Scholar